Home

Kathleen Sebelius

CIK 1654316 · last filed 2026-06-12

Kathleen Sebelius is a corporate insider who has filed 34 SEC Form 4 insider transactions across 4 companies since 2015. The most recent filing, for HUMAW, was dated Jun 12, 2026. Across all open-market trades the lifetime net is +$132.8K, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $36.8K across reported positions. 11 SEC filings were submitted jointly with EXACT SCIENCES CORP.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$36.8K

Companies

4

Total Filings

34

Lifetime Open-Market Net

$132.8K

Filer Profile

Reported Address
C/O DERMIRA, INC.
275 MIDDLEFIELD ROAD, SUITE 150
MENLO PARK, CA 94025
Related Filers
EXACT SCIENCES CORP — 11 joint filings, latest 2025-07-16
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
Humacyte, Inc. (HUMAW) Delisted Director 148,025 $0.00 $133 $88.0K 10 2026-06-12
EXACT SCIENCES CORP (EXAS) Delisted Director 32,671 $104.91 $3.43M $0 9 2024-12-20
Myovant Sciences Ltd. (MYOV) Delisted Director 100 $26.98 $2.7K $44.8K 6 2020-09-17
DERM Director 6,000 $6.14 $36.8K $0 6 2019-06-14

Recent Filings

34 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-06-12 Humacyte, Inc. (HUMAW) Delisted Grant (A) — $0 EDGAR
2026-05-20 Humacyte, Inc. (HUMAW) Delisted Buy (P) +56,818 $50.0K EDGAR
2025-07-16 EXACT SCIENCES CORP (EXAS) Delisted Notice (144) −8,164 -$433.6K EDGAR
2025-06-16 Humacyte, Inc. (HUMAW) Delisted Grant (A) — $0 EDGAR
2025-04-08 Humacyte, Inc. (HUMAW) Delisted Buy (P) +50,000 $66.0K EDGAR
2024-12-20 EXACT SCIENCES CORP (EXAS) Delisted Grant (A) +7,672 $0 EDGAR
2024-09-11 Humacyte, Inc. (HUMAW) Delisted Mixed +1,818 -$78 EDGAR
2024-09-10 HUMA Notice (144) −5,182 -$28.0K EDGAR
2024-06-17 Humacyte, Inc. (HUMAW) Delisted Mixed +39,389 $100.8K EDGAR
2024-06-17 EXACT SCIENCES CORP (EXAS) Delisted Grant (A) +6,889 $0 EDGAR
Showing 1–10 of 34
Page 1 of 4
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.